IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response
Our study shows that IHCH9033, a novel class I HDACi with a desirable pharmacological profile, is a promising drug candidate for FLT3-ITD AML, and suggests a strategy of combining class I HDACis and FLT3is in AML clinical trials to increase efficacy and overcome resistance, thus potentially providing a curative treatment option.
Authors
- Hualiang Jiang (ORCID: https://orcid.org/0000-0003-0656-6315)
- Yingnian Li
- Chengcheng Yu (ORCID: https://orcid.org/0000-0003-3595-0017)
- Jianjun Cheng (ORCID: https://orcid.org/0000-0001-6065-2682)
- Mingyue Yao
- Yu Zhao (ORCID: https://orcid.org/0000-0001-9025-2014)
- Wang Yf (ORCID: https://orcid.org/0000-0001-7737-1406)
- Chengying Xie (ORCID: https://orcid.org/0000-0002-3572-5269)
- Wenzhong Yan (ORCID: https://orcid.org/0000-0003-0420-9138)
- Yujun Chen (ORCID: https://orcid.org/0000-0003-3190-6713)
- Jie Shen (ORCID: https://orcid.org/0000-0001-7330-2446)
- Xiaowei Xu (ORCID: https://orcid.org/0000-0001-9043-2293)
Institutions
- Shanghai Jiao Tong University (CN)
- Chinese Academy of Sciences (CN)
- State Administration of Traditional Chinese Medicine of the People's Republic of China (CN)
- ShanghaiTech University (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Shanghai Institute of Materia Medica (CN)
- Shanghai First People's Hospital (CN)
- Shuguang Hospital (CN)
Publication Details
- Journal
- Experimental Hematology and Oncology
- Published
- 2025-02-15
- DOI
- https://doi.org/10.1186/s40164-025-00605-y
- Citations
- 11
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 8.87
Funders
- National Natural Science Foundation of China